Features

Features

Investors optimistic about continued biotech and medtech IPO resurgence in 2025

When Australian biotech Telix Pharmaceuticals pulled a last-minute plug on its US public listing, it was yet another sign that…

Features

Magazine: US reproductive laws could limit women’s participation in clinical trials

Features

CTO Europe 2024: keep the burden of trials away from patients, say experts

Features

ADCs breach barriers to become mainstream cancer treatment

Features

Flu vaccine strategy on the line as new US leaders anticipated to take charge

Features

How Pfizer management outplayed activist investor Starboard

Features

Trump 2.0 spells global change in pharmaceutical regulation, funding and investment

Features

Magazine: Pharma’s green shift with dry powder inhalers

Features

Are dry powder inhalers the key to sustainable respiratory care?

Frankie Fattorini

Features

How to adapt to choppy waters in biotech ecosystem

Features

Injectables manufacturing ushers in a new era of accessibility

Natasha Spencer-Jolliffe

Features

Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions

Features

What is the pharmacy of the future?

Natasha Spencer-Jolliffe

Features

Preparing for DSCSA transition with tech-led compliance

Natasha Spencer-Jolliffe

Features

A slow start for self-amplifying mRNA vaccines

Frankie Fattorini

Features

Cell and gene therapy approvals drive paradigm change in manufacturing

Features

Magazine: Cell and gene therapy approvals drive paradigm change in manufacturing

Features

Social media algorithms are driving the GLP-1 drugs boom

Features

Blockchain leaders finesse tech to find fake drugs

Natasha Spencer-Jolliffe

Features

Compounding pharmacies caught in counterfeit controversy

Natasha Spencer-Jolliffe

Features

Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship efforts

Features

AI boom set to revolutionise healthcare in Europe

Features

Magazine: Enhancing therapy adherence with prodrugs

Features

After the Lykos debacle, what’s next for psychedelic therapies?

Frankie Fattorini

Features

Into the unknown: How quickly can vaccines be developed for Disease X

Features

Prodrugs and patents: Enhancing therapy adherence and reducing side effects

Features

Are PBMs to blame for high drug prices in the US?

Frankie Fattorini

Features

The most expensive drugs in the US

Features

What is mpox and how big of a threat is it?

Features

Era of ADCs: Pharma companies innovate to stand out in a buzzing market

Akosua Mireku and Irena Maragkou

Features

Pharma casts a wide net to hook opportunities in metabolic disorders

Features

Magazine: Left in limbo: when pharma halts rare disease research

Features

Alzheimer’s: drug delivery and the blood brain barrier conundrum

Features

Inside the efforts to rescue a rare disease gene therapy

Interviews

Drug development costs predicted to soar as BIOSECURE Act gains momentum

Phalguni Deswal

Features

Explainer: Labour has been elected in the UK – now what?

Joshua Silverwood

Features

Does H5N1 avian influenza have pandemic potential?

Features

Left in limbo: When pharma halts rare disease research

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Pharma Technology Focus : Pharmaceutical Technology Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close